By Reuters Staff
(Reuters) - The U.S. Food and Drug Administration on Thursday approved two fixed-dose HIV pills that combine protease inhibitors, both with a boosting agent.
Evotaz from Bristol-Myers Squibb is a once-daily pill containing Reyataz, also known as atazanavir, a protease inhibitor, with the booster cobicistat.
Prezcobix from Janssen Therapeutics combines the protease inhibitor darunavir with cobicistat.
The FDA approved both drugs for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.